2024
The role of international renal disaster preparedness working groups in difficult settings: bridge over troubled water
Yoo K, Chao C, Lee J, Abu-Alfa A. The role of international renal disaster preparedness working groups in difficult settings: bridge over troubled water. Current Opinion In Nephrology & Hypertension 2024, 33: 636-640. PMID: 39234876, DOI: 10.1097/mnh.0000000000001024.Peer-Reviewed Original ResearchImpact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
Elkeraie A, Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaedi A, AlSuwaida A, Arici M, Ecder T, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective. International Journal Of Nephrology And Renovascular Disease 2024, 17: 1-16. PMID: 38196830, PMCID: PMC10771977, DOI: 10.2147/ijnrd.s430532.Peer-Reviewed Original ResearchChronic kidney diseaseSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsDiabetes mellitusKidney diseaseType 2 diabetes mellitusMajor public health concernAldosterone system inhibitorsBetter clinical outcomesCause of deathPublic health concernNephrology referralCKD managementClinical outcomesSystem inhibitorsCardioprotective propertiesEarly initiationTreatment pathwaysConsensus recommendationsHigh riskPatientsBetter careHealth concernEarly detectionHypertension
2023
Biospecimen Repositories in Low- and Middle-Income Countries: Insights From an American University of Beirut and Memorial Sloan Kettering Collaboration
Faraj W, Robson M, Tawil A, Reuter V, Mahfouz R, Cambria R, Saheb N, Ferrer C, Vemuri S, Yaghi M, Kanso M, Abdullah A, Nounou G, Jabbour M, Muenkel K, Kaufman K, Wakim J, Badson S, Wilson R, Houston C, Drobnjak M, Hoballah J, Ziyadeh F, Zaatari G, Brennan M, O'Reilly E, Abu-Alfa A, Abou-Alfa G. Biospecimen Repositories in Low- and Middle-Income Countries: Insights From an American University of Beirut and Memorial Sloan Kettering Collaboration. JCO Global Oncology 2023, 9: e2300140. PMID: 37883726, PMCID: PMC10846789, DOI: 10.1200/go.23.00140.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterMiddle-income countriesPatients age 18 yearsBiospecimen repositoryPatient participation ratesAge 18 yearsPotential participantsDocumentation of reasonsPrimary physicianCancer CenterJoint tissuesTherapeutic interventionsBody sitesPatientsAbnormal tissueConsentFamily membersTissueResearch awarenessAUBParticipation ratesBiospecimensParticipantsCancer genomicsChronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches
Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaaidi A, AlSuwaida A, Arici M, Ecder T, Koraie A, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches. International Journal Of Nephrology And Renovascular Disease 2023, 16: 103-112. PMID: 37051319, PMCID: PMC10084934, DOI: 10.2147/ijnrd.s363133.Peer-Reviewed Original ResearchChronic kidney diseaseManagement of CKDChronic kidney disease managementKidney disease managementManagement of patientsNovel therapeutic optionsTherapeutic optionsKidney diseaseProtective therapyOverall burdenEarly diagnosisAvailable evidenceDisease managementHealthcare specialistsHealthcare systemHealthcare policyPatientsSteering CommitteeBurdenRiskHypertensionComorbiditiesDiabetesReferralTherapy
2020
Collagenofibrotic glomerulopathy in a kidney transplant recipient: A first report
Jdiaa SS, Moeckel GW, Kfoury H, Medawar WA, Abu‐Alfa A. Collagenofibrotic glomerulopathy in a kidney transplant recipient: A first report. American Journal Of Transplantation 2020, 21: 1948-1952. PMID: 33206467, DOI: 10.1111/ajt.16399.Peer-Reviewed Case Reports and Technical NotesConceptsKidney transplant recipientsCollagenofibrotic glomerulopathyTransplant recipientsRenal dysfunctionType 3 fibresProgressive diseaseKidney diseaseDefinitive diagnosisUnknown causeRare diseaseDiseaseFirst caseRecipientsFirst reportHematuriaProteinuriaGlomerulopathyPatientsDysfunctionGlomeruliDiagnosisProgressionKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
Małyszko J, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler D, Winkelmayer W, Porta C, Participants C, Abu-Alfa A, Amer H, Beutel G, Chapman J, Chen X, Chudek J, Cosmai L, Danesi R, De Stefano F, Iseki K, Jaimes E, Jhaveri K, Jurczyszyn A, Kazancioğlu R, Kitchlu A, Kollmannsberger C, Lahoti A, Li Y, Macía M, Matsubara T, Mitropoulos D, Noiri E, Perazella M, Ronco P, Rosner M, Romeo M, Sprangers B, Stadler W, Stevens P, Tesař V, da Costa e Silva V, Vesole D, Vijayan A, Viklický O, Workeneh B, Yanagita M, Zakharova E. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International 2020, 98: 1407-1418. PMID: 33276867, DOI: 10.1016/j.kint.2020.07.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseHematological malignanciesControversies ConferenceKidney transplantationModerate stage chronic kidney diseaseKDIGO Controversies ConferenceAcute kidney injuryKidney transplant recipientsBurden of cancerKidney injuryTransplant recipientsKidney transplantRegistry analysisMultiple myelomaClinical challengeCancer riskGlobal outcomeMalignancyCancerPatientsDiseaseTransplantationBidirectional relationshipRiskStrategic plan for integrated care of patients with kidney failure
Harris DCH, Davies SJ, Finkelstein FO, Jha V, Bello AK, Brown M, Caskey FJ, Donner JA, Liew A, Muller E, Naicker S, O’Connell P, Filho RP, Vachharajani T, Groups S, Abu Alfa A, Ashuntantang G, Brown E, Cullis B, Dreyer G, Eke F, Garcia G, Goh B, Hemmelgarn B, Hou F, Iyengar A, Johnson D, Levin N, Luyckx V, Martin D, McCulloch M, Mengistu Y, Moosa M, Morton R, Niang A, Obrador G, Okpechi I, Ossareh S, Shah K, Sola L, Swanepoel C, Tchokhonelidze I, Tonelli M, Trask M, Kazancioglu R, Twahir A, Walker R, Were A, Yang C, Yeates K, Zakharova E, Zuniga C. Strategic plan for integrated care of patients with kidney failure. Kidney International 2020, 98: s117-s134. PMID: 33126957, DOI: 10.1016/j.kint.2020.07.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
Porta C, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler D, Winkelmayer W, Małyszko J, Participants C, Abu-Alfa A, Amer H, Beutel G, Chapman J, Chen X, Chudek J, Cosmai L, Danesi R, De Stefano F, Iseki K, Jaimes E, Jhaveri K, Jurczyszyn A, Kazancioğlu R, Kitchlu A, Kollmannsberger C, Lahoti A, Li Y, Macía M, Matsubara T, Mitropoulos D, Noiri E, Perazella M, Ronco P, Rosner M, Romeo M, Sprangers B, Stadler W, Stevens P, Tesař L, da Costa e Silva V, Vesole D, Vijayan A, Viklický O, Workeneh B, Yanagita M, Zakharova E. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney International 2020, 98: 1108-1119. PMID: 33126977, DOI: 10.1016/j.kint.2020.06.046.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseSolid organ malignanciesControversies ConferenceKidney impairmentKidney diseaseKidney cancerKDIGO Controversies ConferenceSetting of malignancyIncidence of cancerAreas of controversyOrgan malignanciesTreatment landscapeKidney functionOncology patientsMedical oncologyPalliative careRenal issuesPatient outcomesNovel therapiesCritical careMalignancyAnticancer treatmentCancerPatientsCancer treatment
2019
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
House A, Wanner C, Sarnak M, Piña I, McIntyre C, Komenda P, Kasiske B, Deswal A, deFilippi C, Cleland J, Anker S, Herzog C, Cheung M, Wheeler D, Winkelmayer W, McCullough P, Participants C, Abu-Alfa A, Amann K, Aonuma K, Appel L, Baigent C, Bakris G, Banerjee D, Boletis J, Bozkurt B, Butler J, Chan C, Costanzo M, Dubin R, Filippatos G, Gikonyo B, Gikonyo D, Hajjar R, Iseki K, Ishii H, Knoll G, Lenihan C, Lentine K, Lerma E, Macedo E, Mark P, Noiri E, Palazzuoli A, Pecoits-Filho R, Pitt B, Rigatto C, Rossignol P, Setoguchi S, Sood M, Störk S, Suri R, Szummer K, Tang S, Tangri N, Thompson A, Vijayaraghavan K, Walsh M, Wang A, Weir M. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 95: 1304-1317. PMID: 31053387, DOI: 10.1016/j.kint.2019.02.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseDialysis-dependent chronic kidney diseaseNondialysis chronic kidney diseaseHeart failureKidney diseaseEjection fractionGlobal outcomeKidney transplant patientsReduced ejection fractionControversies ConferenceTransplant patientsBreakout group discussionsDiseaseOutcomesFailureHFpEFPatientsGroup discussionsPrevalenceIncidenceDiagnosisPreventionDialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Chan C, Blankestijn P, Dember L, Gallieni M, Harris D, Lok C, Mehrotra R, Stevens P, Wang A, Cheung M, Wheeler D, Winkelmayer W, Pollock C, Participants C, Abu-Alfa A, Bargman J, Bleyer A, Brown E, Davenport A, Davies S, Finkelstein F, Flythe J, Goffin E, Golper T, Gómez R, Hamano T, Hecking M, Heimbürger O, Hole B, Hothi D, Ikizler T, Isaka Y, Iseki K, Jha V, Kawanishi H, Kerr P, Komenda P, Kovesdy C, Lacson E, Laville M, Lee J, Lerma E, Levin N, Lichodziejewska-Niemierko M, Liew A, Lindley E, Lockridge R, Madero M, Massy Z, McCann L, Meyer K, Morton R, Nadeau-Fredette A, Okada H, Perez J, Perl J, Polkinghorne K, Riella M, Robinson B, Rocco M, Rosansky S, Rotmans J, Roblero M, Tangri N, Tonelli M, Tong A, Tsukamoto Y, Tungsanga K, Vachharajani T, van Loon I, Watnick S, Weiner D, Wilkie M, Zakharova E. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 96: 37-47. PMID: 30987837, DOI: 10.1016/j.kint.2019.01.017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEnd-stage kidney diseaseDialysis initiationKidney diseaseModality choiceGoals of careNumber of patientsPatient-centered goalsDiverse health care systemsHealth care jurisdictionsAreas of controversyHealth care systemControversies ConferenceMaintenance dialysisDialysis modalityPatient goalsPatient educationIndividualized carePatient involvementPatient experienceGlobal outcomeCare systemDialysisPatientsOutcomesDisease
2013
Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients
Abou-Mrad RM, Abu-Alfa AK, Ziyadeh FN. Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. American Journal Of Physiology. Renal Physiology 2013, 305: f613-f617. PMID: 23825072, DOI: 10.1152/ajprenal.00173.2013.BooksConceptsChronic kidney diseaseKidney diseaseBariatric surgeryModerate chronic kidney diseaseWeight reduction regimensIntentional weight lossRenal functional changesWeight loss interventionHigh-protein dietGlomerular hyperfiltrationPerioperative complicationsObese patientsRenal damageLoss interventionAdvanced stageFunctional changesModest riskWeight lossDiseaseAlbuminuriaObesityPatientsSurgeryBeneficial reductionHypertension
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
2010
Experience with outpatient computed tomographic-guided renal biopsy.
Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.Peer-Reviewed Original ResearchConceptsNative kidney biopsiesKidney biopsyRenal biopsyPost-biopsy observation periodInpatient observation periodObservation periodLow complication rateTime of admissionYale-New Haven Medical CenterDuration of procedureInstances of deathHemoglobin concentration changesDetectable bleedingSerum creatinineComplication rateMean ageRenal sizeAdequate tissueMedical CenterOutpatient unitDiagnostic tissueBiopsyLaboratory dataTransfusionPatientsRenal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature
Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.Peer-Reviewed Case Reports and Technical NotesConceptsNephrogenic systemic fibrosisRenal transplantationSystemic fibrosisSymptoms of NSFEarly renal transplantationUnderwent renal transplantationRare fibrosing disorderStandard therapy existsRenal functionFibrosing disorderRenal diseaseCase reportTherapy existsPatient's lesionTherapeutic modalitiesTransplantationPatientsLesionsFibrosisPhotopheresisPlasmapheresisImatinibSymptomsCareful considerationDisease
2009
Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation
Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu‐Alfa A, Cowper SE, Bucala R, Gomer RH. Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Journal Of Magnetic Resonance Imaging 2009, 30: 1284-1288. PMID: 19937928, PMCID: PMC2787835, DOI: 10.1002/jmri.21800.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsNephrogenic systemic fibrosisSerum amyloid PFibrocyte differentiationDifferentiation of monocytesNSF patientsBlood mononuclear cellsHemodialysis patientsInterleukin-12Mononuclear cellsPurified monocytesFibroblast-like cellsFibrotic lesionsHealthy controlsSystemic fibrosisAmyloid PContrast agentsPatientsMonocytesDifferentiation inhibitorWiley-LissFibrocytesOmniscanDifferentiation protocolsCellsSuccessful Use of Intraperitoneal Daptomycin in the Treatment of Vancomycin-Resistant Enterococcus Peritonitis
Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK. Successful Use of Intraperitoneal Daptomycin in the Treatment of Vancomycin-Resistant Enterococcus Peritonitis. American Journal Of Kidney Diseases 2009, 54: 538-541. PMID: 19237231, DOI: 10.1053/j.ajkd.2008.12.017.Peer-Reviewed Case Reports and Technical NotesConceptsIntraperitoneal daptomycinPeritoneal dialysis-associated peritonitisDialysis-associated peritonitisEnterococcus faecium peritonitisSuch resistant organismsPeritoneal dialysis therapyTreatment of patientsVancomycin-resistant enterococciDialysis therapyDialysate exchangePeritonitisResistant organismsPatientsDaptomycinDextrose solutionAdditional studiesTreatmentSuccessful useRelapseDosingTherapyPharmacokineticsInfection
2008
The Association of Hashimoto Disease and Congo Red Negative Amyloidosis
Chaiban JT, Kalache SM, Salti I, Abu Alfa A, Shabb N. The Association of Hashimoto Disease and Congo Red Negative Amyloidosis. The American Journal Of The Medical Sciences 2008, 336: 293-296. PMID: 18794630, DOI: 10.1097/maj.0b013e31815b9d51.Peer-Reviewed Original ResearchConceptsCongo red stainHashimoto's thyroiditisPrimary amyloidosisMultiple organ involvementRed stainMonoclonal immunoglobulin light chainsOrgan involvementRenal failureHeart failureHashimoto's diseaseAmyloid depositionEnlarged tongueRare caseImmunoglobulin light chainsSystemic amyloidosisExtracellular depositionImmunofixation studiesAmyloidosisUltrastructural featuresThyroiditisPatientsLight chainStainEarly stagesBiopsyNephrogenic systemic fibrosis—Implications for nephrologists
Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—Implications for nephrologists. European Journal Of Radiology 2008, 66: 208-212. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.BooksConceptsRisk of NSFChronic kidney diseaseNephrogenic systemic fibrosisContrast-induced nephropathyAdvanced chronic kidney diseaseDevelopment of NSFAdministration of gadoliniumErythropoietin therapyNephrologist's perspectiveKidney diseaseMetabolic acidosisRisk factorsMineral metabolismSystemic fibrosisNephrologist's roleHigh dosesGd-CARecent evidenceRiskContrast agentsNephropathyNephrologistsPatientsFibrosisAcidosis
2006
Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders
BREWSTER UC, CIAMPI MA, ABU‐ALFA A, REILLY RF. Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders. Nephrology 2006, 11: 142-146. PMID: 16669977, DOI: 10.1111/j.1440-1797.2006.00544.x.Peer-Reviewed Original ResearchConceptsCalcium-containing bindersSerum phosphorus concentrationLower serum bicarbonate concentrationEnd-stage renal diseaseCalcium-phosphorus productSerum bicarbonate concentrationSevelamer hydrochloridePhosphate bindersCalcium-containing phosphate bindersElevated calcium-phosphorus productHigher serum phosphorus concentrationsMmol2/L2Retrospective chart reviewLong-term efficacyCa-P productLong-term comparative studiesBicarbonate concentrationESRD patientsChart reviewRenal diseaseCalcium loadPatientsLong-term comparisonTarget goalsEfficacy
2004
Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration
Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S, Group O. Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration. Journal Of The American Society Of Nephrology 2004, 16: 546-554. PMID: 15625070, DOI: 10.1681/asn.2004090793.Peer-Reviewed Original ResearchConceptsIcodextrin groupNegative net ultrafiltrationNet ultrafiltrationPeritoneal ultrafiltrationWeek 2Week 1Control groupDouble-blind trialPercentage of patientsAutomated Peritoneal DialysisPeritoneal dialysisTreatment groupsControlled EvaluationHigh transportersClinical observationsIcodextrinStudy periodBaselineLong dwellPatientsDextroseSolute removalGroupEfficiency ratioMulticenter